Search

Your search keyword '"Marcheselli L."' showing total 292 results
Start Over Author "Marcheselli L."
292 results on '"Marcheselli L."'

1. Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy

Author

Salati M, Marcheselli L, Messina C, Merz V, Messina M, Carotenuto P, Caputo F, Gelsomino F, Spallanzani A, Reggaiani Bonetti L, Caramaschi S, Luppi G, Dominici M, and Ghidini M

Subjects
biliary tract cancer, chemotherapy, second-line, prognostic score, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Massimiliano Salati,1,2 Luigi Marcheselli,1 Carlo Messina,3 Valeria Merz,3,4 Marco Messina,5 Pietro Carotenuto,6 Francesco Caputo,1 Fabio Gelsomino,1 Andrea Spallanzani,1 Luca Reggiani Bonetti,7 Stefania Caramaschi,7 Gabriele Luppi,1 Massimo Dominici,1 Michele Ghidini8 1Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 2PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy; 3Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy; 4Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy; 5Oncology Unit, Fondazione San Raffaele-Giglio, Cefalu’, Palermo, Italy; 6Telethon Institute of Genetics and Medicine, Pozzuoli, 80078, Napoli, Italy; 7Pathology Section, University Hospital of Modena, Modena, Italy; 8Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyCorrespondence: Massimiliano Salati, PhD Program Clinical and Experimental Medicine, University Hospital of Modena, Modena Cancer Centre, via del Pozzo 71, Modena, 41125, Italy, Tel +39/0594223808, Fax +39/0594222647, Email massimiliano.salati@unimore.itBackground: The role of second-line chemotherapy in advanced biliary cancers (ABCs) has only recently been established in phase III randomized trial and the optimal selection of patients most likely to benefit from it remains challenging.Methods: A cohort of 98 ABC treated second-line chemotherapy was used as a developmental dataset to identify covariates independently associated with overall survival (OS). Kaplan–Meier analysis was used to investigate the association between variables and OS and those retaining statistically significance were combined in a multiplexed score.Results: The following pretreatment variables were independently associated with OS: ECOG PS > 0, peritoneal disease, LDH > 430 UI/L, albumin < 3.5 gr/dL, gamma-GT > 100 UI/L, sodium < 140 mEq/L, absolute lymphocyte count < 1000/mmc, and PFS to first-line < 6 months. Based on these results, a scoring system was developed that identified three subgroups with statistically different OS: low-risk (mOS 18 months), intermediate-risk (mOS 9.4 months) and high-risk (mOS 2.9 months) (p < 0.001). The prognostic model was both internally and externally validated in a multicentre cohort of 120 ABCs.Conclusion: The Modena score is a multiplexed scoring system capable of accurately risk-stratified ABCs treated with second-line chemotherapy. Based on its reproducibility, usability and generalizability, it has the potential for assisting therapeutic decision-making in the clinic and risk-stratification in future trials.Graphical Abstract: Keywords: biliary tract cancer, chemotherapy, second-line, prognostic score, survival

Published
2022

2. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, Luminari, Stefano, Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97

Published
2024

3. Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0

Author

Skrypets, T., primary, Chauvie, S., additional, Manni, M., additional, Fallanca, F., additional, Racca, M., additional, Hitz, F., additional, Advani, R., additional, Ramos, C. D., additional, Miranda, E., additional, Tomuleasa, C., additional, Minoia, C., additional, Marino, D., additional, Noyan‐Atalay, F., additional, Stepanishyna, Y., additional, De Maggi, A., additional, Marcheselli, L., additional, Chang, C., additional, Federico, M., additional, and Luminari, S., additional

Published
2023
Full Text
View/download PDF

4. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., Merli F., Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., and Merli F.

Abstract

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n 5 388) or required hospitalization (n 5 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

Published
2022

5. The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts

Author

Ferri P, Guadi M, Marcheselli L, Balduzzi S, Magnani D, and Di Lorenzo R

Subjects
Shiftwork, Night work, Health, Sleep disorders, Job satisfaction, Nurses, Public aspects of medicine, RA1-1270
Abstract

Paola Ferri,1 Matteo Guadi,1 Luigi Marcheselli,1 Sara Balduzzi,1 Daniela Magnani,1 Rosaria Di Lorenzo2 1Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, 2Department of Mental Health, AUSL di Modena, Service of Psychiatric Diagnosis and Treatment, Modena, Italy Background: Shift work is considered necessary to ensure continuity of care in hospitals and residential facilities. In particular, the night shift is one of the most frequent reasons for the disruption of circadian rhythms, causing significant alterations of sleep and biological functions that can affect physical and psychological well-being and negatively impact work performance.Objectives: The aim of this study was to highlight if shift work with nights, as compared with day work only, is associated with risk factors predisposing nurses to poorer health conditions and lower job satisfaction.Methods: This cross-sectional study was conducted from June 1, 2015 to July 31, 2015 in 17 wards of a general hospital and a residential facility of a northern Italian city. This study involved 213 nurses working in rotating night shifts and 65 in day shifts. The instrument used for data collection was the “Standard Shift Work Index,” validated in Italian. Data were statistically analyzed.Results: The response rate was 86%. The nurses engaged in rotating night shifts were statistically significantly younger, more frequently single, and had Bachelors and Masters degrees in nursing. They reported the lowest mean score in the items of job satisfaction, quality and quantity of sleep, with more frequent chronic fatigue, psychological, and cardiovascular symptoms in comparison with the day shift workers, in a statistically significant way.Conclusion: Our results suggest that nurses with rotating night schedule need special attention due to the higher risk for both job dissatisfaction and undesirable health effects. Keywords: shift work, night work, health, sleep disorders, job satisfaction, nurses

Published
2016

7. P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY

Author

Drandi, D., primary, Ferrante, M., additional, Zibellini, S., additional, Marcheselli, L., additional, Cappello, E., additional, Borriero, M., additional, Ragaini, S., additional, Dogliotti, I., additional, Varraso, C., additional, Cavallo, F., additional, Ferrari, A., additional, Merli, M., additional, Zamprogna, G., additional, Laurenti, L., additional, Tomasetti, S., additional, Cencini, E., additional, Loseto, G., additional, Finotto, S., additional, Marchetti, M., additional, Re, F., additional, Sica, A., additional, Olivieri, J., additional, Jimenez, C., additional, Puig, N., additional, Cavalloni, C., additional, García-Sanz, R., additional, Varettoni, M., additional, and Ferrero, S., additional

Published
2022
Full Text
View/download PDF

8. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

10. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

Author

Mian, M., Capello, D., Ventre, M. B., Grazio, D., Svaldi, M., Rossi, A., Tsang, R., Gospodarowicz, M. K., Oldani, E., Federico, M., Luminari, S., Marcheselli, L., Pogliani, E. M., Rossini, F., Cabrera, M. E., Martelli, M., Gutierrez-Garcia, G., Busetto, M., Visco, C., Fiegl, M., Rossi, D., Gaidano, G., Cavalli, F., Zucca, E., Rambaldi, A., Cortelazzo, S., and on behalf of the International Extranodal Lymphoma Study Group (IELSG)

Published
2014
Full Text
View/download PDF

14. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Merli, F., primary, Tucci, A., additional, Arcari, A., additional, Rigacci, L., additional, Cavallo, F., additional, Cabras, G., additional, Alvarez, I., additional, Fabbri, A., additional, Re, A., additional, Ferrero, S., additional, Puccini, B., additional, Usai, S. V., additional, Ferrari, A., additional, Cencini, E., additional, Pennese, E., additional, Zilioli, V. R., additional, Marino, D., additional, Balzarotti, M., additional, Cox, M. C., additional, Zanni, M., additional, Rocco, A., additional, Lleshi, A., additional, Botto, B., additional, Hohaus, S., additional, Merli, M., additional, Sartori, R., additional, Gini, G., additional, Nassi, L., additional, Musuraca, G., additional, Tani, M., additional, Bottelli, C., additional, Kovalchuk, S., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Tarantini, G., additional, Chimienti, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Spina, M., additional

Published
2021
Full Text
View/download PDF

15. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Massaro, F., primary, Pavone, V., additional, Stefani, P. M., additional, Botto, B., additional, Pulsoni, A., additional, Patti, C., additional, Cantonetti, M., additional, Visentin, A., additional, Scalzulli, P. R., additional, Rossi, A., additional, Galimberti, S., additional, Cimminiello, M., additional, Gini, G., additional, Musso, M., additional, Sorio, M., additional, Arcari, A., additional, Zilioli, V. R., additional, Bari, A., additional, Mannina, D., additional, Fabbri, A., additional, Pietrantuono, G., additional, Annibali, O., additional, Tafuri, A., additional, Prete, E., additional, Mulè, A., additional, Barbolini, E., additional, Marcheselli, L., additional, Luminari, S., additional, and Merli, F., additional

Published
2021
Full Text
View/download PDF

16. SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE

Author

Zilioli, V. R., primary, Albano, D., additional, Arcari, A., additional, Merli, F., additional, Coppola, A., additional, Besutti, G., additional, Marcheselli, L., additional, Gramegna, D., additional, Muzi, C., additional, Manicone, M., additional, Camalori, M., additional, Ciammella, P., additional, Colloca, G., additional, and Tucci, A., additional

Published
2021
Full Text
View/download PDF

17. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Galimberti, S., additional, Versari, A., additional, Tucci, A., additional, Boccomini, C., additional, Farina, L., additional, Zaja, F., additional, Marcheselli, L., additional, Ferrero, S., additional, Arcaini, L., additional, Pulsoni, A., additional, Musuraca, G., additional, Califano, C., additional, Merli, M., additional, Bari, A., additional, Conconi, A., additional, Giudice, I. del, additional, Re, F., additional, Stefani, P. M., additional, Usai, S. V., additional, Perrone, T., additional, Gini, G., additional, Falini, B., additional, Gattei, V., additional, Manni, M., additional, Ladetto, M., additional, Mannina, D., additional, and Federico, M., additional

Published
2021
Full Text
View/download PDF

18. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Author

Merli, M., primary, Rattotti, S., additional, Spina, M., additional, Re, F., additional, Motta, M., additional, Piazza, F., additional, Orsucci, L., additional, Ferreri, Andrés J.M., additional, Perbellini, O., additional, Dodero, A., additional, Vallisa, D., additional, Pulsoni, A., additional, Santoro, A., additional, Zuccaro, V., additional, Chimienti, E., additional, Russo, F., additional, Visco, C., additional, Zignego, A. L., additional, Marcheselli, L., additional, Luminari, S., additional, Paulli, M., additional, Bruno, R., additional, and Arcaini, L., additional

Published
2021
Full Text
View/download PDF

19. EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Guerra, L., additional, Durmo, R., additional, Chauvie, S., additional, Peano, S., additional, Franceschetto, A., additional, Fallanca, F., additional, Tarantino, V., additional, Pinto, A., additional, Ghiggi, C., additional, Pulsoni, A., additional, Merli, M., additional, Farina, L., additional, Tani, M., additional, Botto, B., additional, Musuraca, G., additional, Falini, B., additional, Ballerini, F., additional, Stefani, P. M., additional, Bolis, S., additional, Pietrantuono, G., additional, Manni, M., additional, Marcheselli, L., additional, Federico, M., additional, and Versari, A., additional

Published
2021
Full Text
View/download PDF

20. AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI

Author

Tucci, A, primary, Musuraca, G, additional, Cavallo, F, additional, Zilioli, V. R, additional, Zanni, M, additional, Pelliccia, S, additional, Mannina, D, additional, Michieli, M, additional, Vallisa, D, additional, Tani, M, additional, Merli, F, additional, Re, F, additional, Marcheselli, L, additional, Campostrini, G, additional, Pagani, C, additional, Grimaldi, D, additional, Liardo, E. V, additional, Re, A, additional, Cox, M. C, additional, and Rossi, G, additional

Published
2021
Full Text
View/download PDF

21. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Tucci, A., primary, Merli, F., additional, Fabbri, A., additional, Mancuso, S., additional, Sartori, R., additional, Storti, S., additional, Luminari, S., additional, Mammi, C., additional, Marcheselli, L., additional, Arcari, A., additional, Cavallo, F., additional, Zilioli, V. R., additional, Bottelli, C., additional, Re, A., additional, Gini, G., additional, Cox, M. C., additional, Puccini, B., additional, Pagani, C., additional, Balzarotti, M., additional, Spina, M., additional, and Rossi, G., additional

Published
2021
Full Text
View/download PDF

22. COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL.

Author

Ferrero, S., Assanto, G. M., Durmo, R., Marcheselli, L., Mantoan, B., Pironti, M., Guerra, L., Boccomini, C., Puccini, B., Pulsoni, A., Pavone, V., Arcari, A., Califano, C., Castellino, C., Bari, A., Conconi, A., Dardanis, D., Chauvie, S., Gattei, V., and Del Giudice, I.

Subjects
FOLLICULAR lymphoma, POSITRON emission tomography, NON-Hodgkin's lymphoma
Abstract

B Discussion: b MRD analysis and PET scan are independent and complementary prognostic tools in FL: a MRD positivity in the two years after immuno-chemotherapy is predictive of POD24 and dismal PFS independently from the EoI PET result. This means that patients scoring PET- at EoI but showing a persistent or reappearing MRD+ signal during the following 24 months had a dismal PFS, superimposable to that of PET+ patients (Figure 1C). B Introduction: b In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease history. [Extracted from the article]

Published
2023
Full Text
View/download PDF

24. The impact of gender and immune system determinants on long-term survival in biliary tract cancer

Author

Salati M., Caputo F., Cerma K., Marcheselli L., Braconi C., Cascinu S., Salati, M., Caputo, F., Cerma, K., Marcheselli, L., Braconi, C., and Cascinu, S.

Subjects
Biliary tract cancer, Gender differences, Immune system determnants
Abstract

Advanced biliary tract cancers are poor prognosis tumors with limited therapeutic options. The conven-tional treatment consists of combination chemotherapy resulting in overall survival of less than 12 months. Recently, a subgroup of patients characterized by an exceedingly fa-vorable prognosis has been reported in the literature. In our study, we assessed the prevalence and provided a clinico-pathological characterization of this subset of patients in the context of daily practice. In particular, we were able to identify female sex and neutrophil-to-lymphocyte ratio as independent predictors of long-term survival. Based on these premises, we deem it necessary to prompt transla-tional research projects aimed at molecularly characterized long-term survivors, particularly focusing on sex-and im-mune-related determinants.

Published
2019

25. SO-12 Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST

Author

Salati, M., primary, Marcheselli, L., additional, Ruvo, N. De, additional, Esposito, G., additional, Fenocchi, S., additional, Cucciarrè, G., additional, Serra, F., additional, Cautero, N., additional, Cabry, F., additional, Gelmini, R., additional, Vittimberga, G., additional, Radi, G., additional, Solaini, L., additional, Morgagni, P., additional, Ercolani, G., additional, Ghidini, M., additional, Grizzi, G., additional, Ratti, M., additional, Gelsomino, F., additional, Luppi, G., additional, Dominici, M., additional, and Spallanzani, A., additional

Published
2020
Full Text
View/download PDF

28. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA

Author

Batlevi, C.L., primary, Sha, F., additional, Alperovich, A., additional, Ni, A., additional, Smith, K., additional, Ying, Z., additional, Hamlin, P., additional, Horwitz, S.M., additional, Kumar, A., additional, Matasar, M., additional, Moskowitz, A.J., additional, Moskowitz, C.H., additional, Noy, A., additional, Palomba, M.L., additional, Portlock, C., additional, Straus, D., additional, Boccomini, C., additional, Tucci, A., additional, Zelenetz, A.D., additional, Seshan, V.E., additional, Luminari, S., additional, Marcheselli, L., additional, Federico, M., additional, and Younes, A., additional

Published
2019
Full Text
View/download PDF

29. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Author

Spina, M., primary, Merli, F., additional, Puccini, B., additional, Cavallo, F., additional, Cabras, M.G., additional, Fabbri, A., additional, Angrilli, F., additional, Zilioli, V.R., additional, Marino, D., additional, Balzarotti, M., additional, Ladetto, M., additional, Cox, M.C., additional, Petrucci, L., additional, Arcari, A., additional, Gini, G., additional, Chiappella, A., additional, Hohaus, S., additional, Musuraca, G., additional, Merli, M., additional, Sartori, R., additional, Nassi, L., additional, Tani, M., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Kovalchuk, S., additional, Bottelli, C., additional, Ferrero, S., additional, Dessì, D., additional, Cencini, E., additional, Pennese, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Tucci, A., additional

Published
2019
Full Text
View/download PDF

30. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

Author

Federico, M., primary, Mannina, D., additional, Versari, A., additional, Ferrero, S., additional, Marcheselli, L., additional, Boccomini, C., additional, Dondi, A., additional, Tucci, A., additional, Guerra, L., additional, Galimberti, S., additional, Cavallo, F., additional, Olivieri, J., additional, Corradini, P., additional, Arcaini, L., additional, Chauvie, S., additional, Del Giudice, I., additional, Rusconi, C., additional, Pinto, A., additional, Molinari, A., additional, Pulsoni, A., additional, Merli, M., additional, Kovalchuk, S., additional, Nassi, L., additional, Bolis, S., additional, Gattei, V., additional, Manni, M., additional, Pileri, S., additional, Brugiatelli, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

32. Prognostic value of PET-CT after fi rst-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies

Author

Trotman, J, Luminari, S, Boussetta, S, Versari, A, Dupuis, J, Tychyj, C, Marcheselli, L, Berriolo-Riedinger, A, Franceschetto, A, Julian, A, Ricard, F, Guerra, L, Haioun, C, Biasoli, I, Tilly, H, Federico, M, Salles, G, Meignan, M, Trotman J., Luminari S., Boussetta S., Versari A., Dupuis J., Tychyj C., Marcheselli L., Berriolo-Riedinger A., Franceschetto A., Julian A., Ricard F., Guerra L., Haioun C., Biasoli I., Tilly H., Federico M., Salles G., Meignan M., Trotman, J, Luminari, S, Boussetta, S, Versari, A, Dupuis, J, Tychyj, C, Marcheselli, L, Berriolo-Riedinger, A, Franceschetto, A, Julian, A, Ricard, F, Guerra, L, Haioun, C, Biasoli, I, Tilly, H, Federico, M, Salles, G, Meignan, M, Trotman J., Luminari S., Boussetta S., Versari A., Dupuis J., Tychyj C., Marcheselli L., Berriolo-Riedinger A., Franceschetto A., Julian A., Ricard F., Guerra L., Haioun C., Biasoli I., Tilly H., Federico M., Salles G., and Meignan M.

Abstract

Background: The value of 18F-fl uorodeoxyglucose (FDG) PET-CT (PET) imaging in response assessment after fi rst-line rituximab chemotherapy for follicular lymphoma has been documented. We analysed the application of the fi ve-point Deauville scale (5PS; used to score FDG uptake on PET images) in a large cohort derived from three studies, to assess the correlation between post-induction PET status and survival in patients with follicular lymphoma. Methods: In this pooled analysis, we used data from three multicentre prospective studies of fi rst-line rituximab chemotherapy for patients with high-tumour-burden follicular lymphoma (the PRIMA study, the PET-Folliculaire study, and the Fondazione Italiana Linfomi FOLL05 study). Patients included in this analysis received at least six cycles of rituximab and chemotherapy before response assessment with conventional contrast-enhanced CT and PET low-dose CT (PET). We included only patients who had a PET scan within 3 months of the last dose of induction rituximab. Patient data, including conventional CT-based response assessment, were recorded for all patients undergoing PET review. Scans undergoing central PET review were scored independently by three reviewers according to the 5PS. The primary endpoints were progression-free survival and overall survival according to the 5PS score of post-induction PET scan (ie, positive [≥4 points] or negative [<4 points]), analysed in the central review population. Findings: Between Dec 24, 2004, and Sept 22, 2010, 439 of the patients enrolled in the three studies underwent local PET assessment, 246 of whom had centrally reviewed post-induction scans. 41 (17%) of 246 patients had a positive post-induction PET scan according to a cutoff of 4 or higher on the 5PS, with substantial reporter concordance. With a median follow-up of 54.8 months (IQR 39.7-68.5; range 7.7-90.1), the hazard ratio (HR) for progression-free survival for patients with a positive PET scan versus those with a nega

Published
2014

34. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

Author

Federico, M., primary, Caballero, D., additional, Marcheselli, L., additional, Tarantino, V., additional, Sarkozy, C., additional, Lopez Guillermo, A., additional, Wondergem, M., additional, Kimby, E., additional, Rusconi, C., additional, Zucca, E., additional, Montoto, S., additional, da Silva, M.G., additional, Aurer, I., additional, Paszkiewicz-Kozik, E., additional, Cartron, G., additional, Morschhauser, F., additional, Alcoceba, M., additional, Chamuleau, M., additional, Lockmer, S., additional, Minoia, C., additional, Issa, D., additional, Alonso, S., additional, Conte, L., additional, Salles, G., additional, and Coiffier, B., additional

Published
2017
Full Text
View/download PDF

35. DEVEC: A PHASE II STUDY OF METRONOMIC CHEMOTHERAPY IN ELDERLY NON-FIT PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS (PROMOTED BY FIL)

Author

Cox, M.C., primary, Musuraca, G., additional, Arcari, A., additional, Fabbri, A., additional, Gini, G., additional, Tani, M., additional, Tucci, A., additional, Marcheselli, L., additional, Storti, S., additional, Di Landro, F., additional, Battistini, R., additional, Anticoli Borza, P., additional, Casaroli, I., additional, Zoli, V., additional, Fabbri, F., additional, Aroldi, A., additional, Naso, V., additional, Bianchi, M., additional, Borgo, E., additional, Ferranti, A., additional, Dondi, A., additional, Levis, A., additional, Tafuri, A., additional, and Merli, F., additional

Published
2017
Full Text
View/download PDF

36. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY

Author

Luminari, S., primary, Tarantino, V., additional, Anastasia, A., additional, Boccomini, C., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Ferrari, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Vallisa, D., additional, Balzarotti, M., additional, Cox, M.C., additional, Freilone, R., additional, Marcheselli, L., additional, Dondi, A., additional, Manni, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

37. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

Author

Luminari, S., primary, Marcheselli, L., additional, Manni, M., additional, Anastasia, A., additional, Vitolo, U., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Fama, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Tarantino, V., additional, Bellei, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

38. The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial.

Author

Guerra, L., Chauvie, S., Marcheselli, L., Bergesio, F., Durmo, R., Peano, S., Franceschetto, A., Fallanca, F., Pinto, A., Ghiggi, C., Pulsoni, A., Merli, M., Farina, L., Tani, M., Boccomini, C., Musuraca, G., Falini, B., Ballerini, F., Stefani, P., and Bolis, S. A. M.

Subjects
FOLLICULAR lymphoma, SPLEEN, PROGRESSION-free survival, PROGNOSIS
Abstract

In the whole population of 690 patients, the tMTV threshold to categorized low and high tumor burden was 224 and 194 ml with and without sMTV, respectively. During the segmentation procedure, it has been observed that frequently spleen MTV (sMTV) heavily influenced the tMTV value, particularly in case of diffuse spleen uptake included in tMTV calculation. [Extracted from the article]

Published
2023
Full Text
View/download PDF

39. Empathy and burnout: an analytic cross-sectional study among nurses and nursing students

Author

Paola Ferri, Guerra, E., Marcheselli, L., Cunico, L., and Di Lorenzo, R.

Subjects
Adult, Male, burnout, Adolescent, analytic cross-sectional study, Nursing, Middle Aged, nurses, Young Adult, Cross-Sectional Studies, Sex Factors, Italy, Humans, Female, Empathy, empathy, Education, Nursing, analytic cross-sectional study, empathy, burnout, nursing students, nurses, Burnout, Professional, nursing students
Abstract

Empathy is an essential element of good nursing care associated with increased patient satisfaction. Burnout represents chronic occupational stress which diminishes interest in work and reduces patient safety and satisfaction. The purpose of this study was to evaluate the correlation between empathy and burnout in nursing students and nurses.This cross-sectional research was conducted in a sample of 298 nurses and 115 nursing students. Socio-demographic and career information was collected. Balanced Emotional Empathy Scale (BEES) and Maslach Burnout Inventory (MBI) were administered. Data were statistically analysed.63% of our sample answered questionnaires (54% of nurses and 84% of students). The BEES global mean score was slightly inferior to empathy cut-off of 32. In the student group, two BEES dimension scores were statistically significantly higher than nurses (p=0.011 and p=0.007 respectively, t-test). Empathy was negatively related to age (p=0.001, ANOVA). Emotional exhaustion (EE) scores of MBI reported statistically significantly lower levels for students (p0.0001, t-test). EE was negatively related to BEES mean total score in students (r=-0.307, p0.002) and nurses (r=-0.245, p0.002), personal accomplishment of MBI presented positive correlation with BEES mean total scores in students (r=0.319, p0.002) and nurses (r=0.266, p0.001, Pearson's correlation). Female students showed superior empathy capacity in comparison to male students in all 5 dimensions of BEES (p0.001), whereas females nurses in only one dimension (p0.001).Our data suggest empathy declines with age and career. High levels of empathy can be protective against burnout development, which, when presents, reduces empathy.

Published
2015

42. Il bilancio idrico consortile come strumento per un utilizzo sostenibile della risorsa idrica

Author

TAGLIOLI, GIUSEPPE, Marcheselli L., Taglioli G., and Marcheselli L.

Subjects
BILANCIO IDRICO CONSORTILE, EFFICIENZA, RISPARMIO IDRICO, VERIFICA, IDRAULICA AGRARIA
Abstract

Viene presentato un esempio di bilancio idrico consortile valutando gli ingressi idrici in un sistema di bonifica del parmigiano e le diverse destinazioni idriche all'interno del comprensorio tra perdite dai canali,perdite di sitema,distribuzioni irrigue. Si è potuto constatre come l'efficienza globale del sistema sia collettivo che aziendale risulti modesta (30%) e quindi si è posta in evidenza la necessità di intervenire sia a livello aziendale che consortile.

Published
2007

43. Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

Author

Iannitto, E., Minardi, V., Gobbi, P. G., stefano luminari, Calvaruso, G., Stelitano, C., Baldini, L., Merli, Petrini, M., Marcheselli, L., Mammi, C., Cantis, S., Abbadessa, V., Federico, M., and Iannitto E, Minardi V, Gobbi P, Luminari S, Calvaruso G, Stelitano C, Baldini L, Merli, Petrini M, Marcheselli L,Mammi C, De Cantis S, Abbadessa V, Federico M

Subjects
Hodgkin disease, chemotherapy
Published
2007

45. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Author

Sacchi, S., primary, Marcheselli, R., additional, Bari, A., additional, Buda, G., additional, Molinari, A. L., additional, Baldini, L., additional, Vallisa, D., additional, Cesaretti, M., additional, Musto, P., additional, Ronconi, S., additional, Specchia, G., additional, Silvestris, F., additional, Guardigni, L., additional, Ferrari, A., additional, Chiapella, A., additional, Carella, A. M., additional, Santoro, A., additional, Di Raimondo, F., additional, Marcheselli, L., additional, and Pozzi, S., additional

Published
2016
Full Text
View/download PDF

46. Determinazione del risparmio idrico attraverso il bilancio idrico consortile

Author

Marcheselli L., TAGLIOLI, GIUSEPPE, AISSA, Marcheselli L., and Taglioli G.

Subjects
DETERMINAZIONE, EFFICIENZA, IRRIGAZIONE, RISPARMIO IDRICO, BILANCIO IDRICO
Abstract

Attraverso il bilancio idrico di un comprensorio di bonifica vengono evidenziate le ripartizioni della risorsa idrica tra le varie perdite idriche e gli utilizzi aziendali

Published
2005

48. R-CHOP vs R-miniCEOP for the initial treatment of elderly 'fit' patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL)

Author

Merli, F, Luminari, S, Rossi, G., Mammi, C., Marcheselli, L., Tucci, A., Ilariucci, F., Chiappella, A., Musso, M., Di Rocco, A., Stelitano, C., Alvarez, I., Baldini, L., Mazza, P., Salvi, F., Arcari, A., Fragasso, A., Gobbi, P. G., Liberati, Anna Marina, and Federico, M.

Subjects
fit patients, R-CHOP, diffuse large B-cell lymphoma, R-miniCEOP, elderly
Published
2012

49. The “Elderly Project” by the Fondazione Italiana Linfomi (FIL): a prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma

Author

Merli, F., primary, Tucci, A., additional, Angrilli, F., additional, Cavallo, F., additional, Cabras, G., additional, Fabbri, A., additional, Mammi, C., additional, Chiappella, A., additional, Gussetti, D., additional, Zilioli, V., additional, Arcari, A., additional, Tani, M., additional, Balzarotti, M., additional, Fedina, A., additional, Marcheselli, L., additional, and Spina, M., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results